MENLO PARK, Calif., Dec. 29, 2014 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today announced that its management will be presenting at the J.P. Morgan 33rd Annual Healthcare Conference on Monday, January 12th in San Francisco.
Nevro management is scheduled to present at 1:30 p.m. PT. Individuals interested in listening to the presentation can access the live audio webcast on the "Investors" section of the Company's website at: www.nevro.com. An archived presentation will be available on the website for two weeks.
About Nevro Corp.
Headquartered in Menlo Park, California, Nevro is a medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. In the United States, the Senza system is limited by federal law to investigational use only. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
SOURCE Nevro Corp.